Have a feature idea you'd love to see implemented?
Let us know!
AQST Aquestive Therapeutics Inc
Price (delayed)
$5.77
Market cap
$525.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.36
Enterprise value
$552.43M
Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan,
Highlights
AQST's equity has surged by 67% year-on-year and by 2.3% since the previous quarter
The company's gross profit has surged by 58% YoY and by 29% QoQ
AQST's net income is down by 14% year-on-year but it is up by 11% since the previous quarter
The debt has grown by 7% YoY
Key stats
What are the main financial stats of AQST
Market
Valuations
Earnings
Shares outstanding
91.06M
Market cap
$525.41M
Enterprise value
$552.43M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
8.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.47
Revenue
$58.36M
EBIT
-$12.82M
EBITDA
-$11.67M
Free cash flow
-$24.91M
Per share
Balance sheet
Liquidity
EPS
-$0.36
Free cash flow per share
-$0.27
Book value per share
-$0.39
Revenue per share
$0.64
TBVPS
$1.29
Total assets
$117.61M
Total liabilities
$153.08M
Debt
$116.88M
Equity
-$35.48M
Working capital
$90.12M
Debt to equity
-3.29
Current ratio
7.49
Quick ratio
6.9
Net debt/EBITDA
-2.31
Margins
Efficiency
Dividend
EBITDA margin
-20%
Gross margin
68.5%
Net margin
-44.1%
Operating margin
-26%
Return on assets
-28.3%
Return on equity
N/A
Return on invested capital
-10.1%
Return on capital employed
-12.4%
Return on sales
-22%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AQST stock price
How has the Aquestive Therapeutics stock price performed over time
Intraday
1.94%
1 week
7.45%
1 month
15.86%
1 year
282.12%
YTD
185.64%
QTD
15.86%
Financial performance
How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$58.36M
Gross profit
$39.97M
Operating income
-$15.19M
Net income
-$25.72M
Gross margin
68.5%
Net margin
-44.1%
The company's gross profit has surged by 58% YoY and by 29% QoQ
Aquestive Therapeutics's operating margin has surged by 57% YoY and by 31% QoQ
The operating income has increased by 46% YoY and by 22% from the previous quarter
Aquestive Therapeutics's gross margin has increased by 26% YoY and by 14% QoQ
Growth
What is Aquestive Therapeutics's growth rate over time
Valuation
What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
8.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.47
The EPS has grown by 16% since the previous quarter and by 10% year-on-year
AQST's equity has surged by 67% year-on-year and by 2.3% since the previous quarter
AQST's P/S is 138% above its last 4 quarters average of 3.7
Aquestive Therapeutics's revenue has increased by 25% YoY and by 13% from the previous quarter
Efficiency
How efficient is Aquestive Therapeutics business performance
The return on sales has grown by 38% since the previous quarter and by 27% year-on-year
The company's return on invested capital rose by 34% QoQ and by 21% YoY
AQST's ROA is up by 29% year-on-year and by 25% since the previous quarter
Dividends
What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AQST.
Financial health
How did Aquestive Therapeutics financials performed over time
The company's total assets is 23% lower than its total liabilities
The company's total assets has surged by 106% YoY but it fell by 9% QoQ
Aquestive Therapeutics's quick ratio has increased by 20% QoQ
AQST's equity has surged by 67% year-on-year and by 2.3% since the previous quarter
The debt has grown by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.